Ursofalk Dosing for 20 kg Patient with Cirrhosis
For a 20 kg patient with cirrhosis (specifically primary biliary cholangitis/PBC), administer Ursofalk at 13-15 mg/kg/day, which equals 260-300 mg daily, given as a single daily dose or divided doses.
Recommended Dose Calculation
The most recent AASLD/AGA guideline from 2026 explicitly recommends 13-15 mg/kg/day as first-line therapy for all patients with PBC 1. This is consistent across both guideline and research evidence.
For your 20 kg patient:
- Minimum dose: 13 mg/kg × 20 kg = 260 mg/day
- Maximum dose: 15 mg/kg × 20 kg = 300 mg/day
Evidence Supporting This Dosing
The 2026 AASLD/AGA guideline provides the strongest recommendation, stating that UDCA 13-15 mg/kg/day should be initiated as first-line therapy for all patients with PBC 1. This dosing range is supported by multiple high-quality studies:
A 1999 dose-response study in early-stage PBC found that 900 mg/day (equivalent to 13.5 mg/kg/day) was the optimum dose, producing the greatest enrichment of UDCA in serum bile acids and the best normalization of liver function tests 2
Research from 2018 emphasizes that 13-15 mg/kg/day is the correct dosage determined by body weight, and notes that a significant number of UK patients are being underdosed, with over one-third of partial responders becoming responders within 2 years after increasing to recommended levels 3
Multiple studies confirm this range improves biochemical markers and may delay disease progression 4, 5, 6
Critical Dosing Pitfalls to Avoid
Underdosing is a common and serious error. The FDA label mentions that doses of 8-10 mg/kg/day were used for gallstone dissolution 7, but this is insufficient for PBC treatment. Research shows that approximately one-third of patients initially classified as partial responders become full responders simply by increasing the dose to the recommended 13-15 mg/kg/day range 3.
Lower doses (300-600 mg/day in adults) have been shown to be significantly less effective than 900-1200 mg/day doses for normalizing liver enzymes 2.
Monitoring and Response Assessment
- Monitor liver enzymes every 3 months for the first year 1
- Assess response at 12 months: adequate response is defined as achieving serum alkaline phosphatase levels <1.5-1.67 times the upper limit of normal and normal total bilirubin 1
- Consider measuring liver stiffness (≥10 kPa by VCTE indicates high-risk for unfavorable outcomes) 1
- If high-risk features are present, assess response at 6 months 1
Context for Cirrhosis
While the evidence primarily addresses PBC (which progresses to biliary cirrhosis), the dosing remains 13-15 mg/kg/day regardless of disease stage. Studies included patients with varying stages of disease, from early-stage to advanced cirrhosis (15-83% with advanced disease), and the same dosing was effective across the spectrum 4, 8.